💊Daiichi Sankyo, Inc. Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline
Basking Ridge, NJ (February 28, 2018) – Daiichi Sankyo, Inc. (“the Company”) announced today that it will reorganize its U.S. Commercial organization as it continues to maximize opportunities for its current portfolio and prepare for its upcoming oncology pipeline. The U.S. restructuring will streamline the Company’s operations, enable it to best serve its current patients and maximize its contribution to the development of medicines that change the standard of care. As part of the reorganization, the Company will reduce headcount by approximately 280 employees from various locations in the U.S.
https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006819.html